Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Two Researchers Fired After Girl Died Seven Days Following a Gene-Editing Infusion Into Her Spinal Fluid

4 hours ago 5

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

An Official Probe Confirms Warning Signs Were Missed

Shanghai authorities have dismissed two researchers after an official investigation found that an experimental gene-editing treatment went ahead despite safety warnings and ended in the death of a 6-year-old girl, a death that was then left out of a published scientific paper.

The girl had Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder with no effective treatment, Sixth Tone reported. She received the customized therapy at Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, on March 24, 2025, and died seven days later.

At an emergency review on April 2, 2025, the hospital's ethics committee attributed the death to thrombotic microangiopathy, a complication of gene therapy in which small blood clots damage organs, and ordered the study terminated.

The investigators concluded that the research team did not promptly share a primate safety report with the clinical study's lead investigator, that the hospital's ethics committee approved the study without enough toxicology and safety evidence, and that the consent form did not prominently state the risk of death.

Fired, Barred and Demoted

The two researchers dismissed are Qiu Zilong, deputy director of the Songjiang Research Institute at Shanghai Jiao Tong University School of Medicine, and Yang Kan, an associate researcher at Xinhua Hospital and first and corresponding author of the related paper. Both were barred for five years from science and technology programs and awards and entered into a national database of serious research integrity violations.

Others were punished too. The clinical study's lead investigator, identified by the surname Yu, was removed as head of the hospital's research department and demoted. The head of the ethics committee office, surnamed Shi, was also removed and demoted. Xinhua Hospital received an administrative penalty, and other officials faced disciplinary action.

Money was part of the case — the family contributed 5.3 million yuan, about $800,000, to the research and separately gave researchers about 1.06 million yuan in cash and gifts, including expensive liquor and electronics. Investigators said the money and gifts were returned or surrendered.

In a statement, the investigators said institutions "must recognize the high risks associated with clinical studies."Shanghai's health commission said it would soon inspect clinical research involving emerging biomedical technologies.

How a Hidden Death Came to Light

The death might have stayed hidden without outside reporting. In July 2026, a joint investigation by Science and Retraction Watch revealed the fatal treatment. The girl, given the pseudonym Mei, had received trillions of engineered viruses carrying a base editor, a precise form of CRISPR gene editing, infused into her spinal fluid, the Genetic Literacy Project summarized.

Her parents provided documents to reporters, including a primate study report showing the treatment had caused serious organ damage in four monkeys. Science reported that the parents asked Qiu to withdraw the related paper because they feared it could mislead other families.

That paper, published in Nature in February 2026, described using gene editing to fix a single DNA error in mouse brain cells and suggested monkey tests supported possible human use. It did not mention the girl's death. Investigators found no data fabrication, but they identified discrepancies between the described and actual methods and undisclosed financial conflicts involving four researchers. Nature has attached an editor's note to the paper, according to CASRAI. No retraction has been reported.

Lessons for a Fast-Growing Field

The case lands at a sensitive moment for in-body gene editing. In 2025, a U.S. infant known as Baby KJ was treated with a personalized base-editing therapy, a result Science named a runner-up for its Breakthrough of the Year. That success raised hopes that similar custom treatments could reach other children with rare diseases.

The Shanghai case shows the risks of moving too fast — the study ran as an investigator-initiated trial, a pathway that lets hospitals test new therapies with local ethics review rather than national regulatory approval. China's new rules for such trials, implemented in May, limit which sites can run them and add requirements, Fierce Biotech reported.

Fierce also noted a separate case reported by Stat, in which a boy in an investigator-initiated trial for Duchenne muscular dystrophy died after a CRISPR-based treatment. Both cases involved severe immune reactions to high-dose, virus-delivered gene therapies and a lack of disclosure.

Authorities will also require multiple organizations to submit written self-examinations and fix the failings identified, and they plan to strengthen oversight of clinical trials for new biomedical technologies such as gene-editing therapies, according to Fierce Biotech.

Several questions remain. Investigators have not detailed the hospital's administrative penalty, and it is unclear whether Nature will take further action on the paper. The findings also do not show whether base editing itself or the delivery method drove the fatal reaction.

The Shanghai findings also matter for patients outside China. Many experimental gene therapies are developed through international collaborations, and journals rely on authors to report serious adverse events. When a death is left out of a paper, other researchers may build on incomplete safety data.

For families considering experimental gene therapy, the case highlights practical questions to ask. Is the trial approved by a national regulator? Have all animal safety results been shared? Does the consent form clearly explain the risk of death? Families can also check trial registries and seek a second opinion from an independent specialist.

Nature World News will follow any action by the journal and the results of Shanghai's planned inspections.

What Readers Want to Know

What happened to the girl? A 6-year-old with Snijders Blok-Campeau syndrome died seven days after receiving an experimental gene-editing therapy at Xinhua Hospital in Shanghai in March 2025.

Who was punished? Researchers Qiu Zilong and Yang Kan were fired and barred for five years. Others were demoted, and the hospital was penalized.

What did investigators find? A primate safety report was not promptly shared, ethics review was inadequate, and the consent form did not clearly state the risk of death.

How was the death revealed? A joint investigation by Science and Retraction Watch reported it in July 2026.

Was the Nature paper retracted? No retraction has been reported. The journal attached an editor's note.

What does this mean for gene editing? It raises pressure for stronger oversight and full disclosure in first-in-human trials.

© 2026 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway